Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

OBJECTIVE To determine whether the rate of serious infection is higher in anti-tumor necrosis factor (anti-TNF)-treated rheumatoid arthritis (RA) patients compared with RA patients treated with traditional disease-modifying antirheumatic drugs (DMARDs). METHODS This was a national prospective observational study of 7,664 anti-TNF-treated and 1,354 DMARD-treated patients with severe RA from the British Society for Rheumatology Biologics Register. All serious infections, stratified by site and organism, were included in the analysis. RESULTS Between December 2001 and September 2005, there were 525 serious infections in the anti-TNF-treated cohort and 56 in the comparison cohort (9,868 and 1,352 person-years of followup, respectively). The incidence rate ratio (IRR), adjusted for baseline risk, for the anti-TNF-treated cohort compared with the comparison cohort was 1.03 (95% confidence interval 0.68-1.57). However, the frequency of serious skin and soft tissue infections was increased in anti-TNF-treated patients, with an adjusted IRR of 4.28 (95% confidence interval 1.06-17.17). There was no difference in infection risk between the 3 main anti-TNF drugs. Nineteen serious bacterial intracellular infections occurred, exclusively in patients in the anti-TNF-treated cohort. CONCLUSION In patients with active RA, anti-TNF therapy was not associated with increased risk of overall serious infection compared with DMARD treatment, after adjustment for baseline risk. In contrast, the rate of serious skin and soft tissue infections was increased, suggesting an important physiologic role of TNF in host defense in the skin and soft tissues beyond that in other tissues.

[1]  D. Macdonald,et al.  Tumour necrosis factor alpha is pro‐inflammatory in normal human skin and modulates cutaneous adhesion molecule expression , 1995, The British journal of dermatology.

[2]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[3]  I. Nestorov.  Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.

[4]  J. Kremer,et al.  Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[5]  M. Braun,et al.  Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. , 2003, Arthritis and rheumatism.

[6]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[7]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Silman,et al.  British Society for Rheumatology Biologics Register , 2003, Annals of the rheumatic diseases.

[9]  Kathleen A Snella,et al.  Listeria Meningitis Associated with Infliximab , 2004, The Annals of pharmacotherapy.

[10]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[11]  C. Johansen,et al.  Tumor necrosis factor-α-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor κB , 2005 .

[12]  J. Ledingham,et al.  Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). , 2005, Rheumatology.

[13]  Pilar Barrera,et al.  Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. , 2003, Arthritis and rheumatism.

[14]  C. Dinarello.  Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. , 2005, The Journal of rheumatology. Supplement.

[15]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[16]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[17]  M. Feldmann,et al.  The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. , 2004, Best practice & research. Clinical rheumatology.

[18]  H. P. McNeil,et al.  Disseminated Salmonella typhimurium infection secondary to infliximab treatment. , 2004, Arthritis and rheumatism.

[19]  A. van der Heide,et al.  Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. , 1994, Annals of the rheumatic diseases.

[20]  M. Wallace,et al.  Infections Associated With Tumor Necrosis Factor-α Antagonists , 2005 .

[21]  U. Müller-Ladner,et al.  Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. , 2002, Arthritis and rheumatism.

[22]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[23]  Richard W. Martin,et al.  Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. , 2005, The Journal of rheumatology.

[24]  T. Schaible,et al.  Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.

[25]  J. Kirwan,et al.  Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. , 1986, British journal of rheumatology.

[26]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[27]  J. Alcocer-Varela,et al.  Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. , 1998, The Journal of rheumatology.

[28]  M. Dougados,et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.

[29]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[30]  C. Griffiths,et al.  Cytokines and Langerhans cell mobilisation in mouse and man. , 2005, Cytokine.

[31]  S. Gabriel,et al.  Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[32]  D. Furst,et al.  Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.

[33]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[34]  V. Strand,et al.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.

[35]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.